Globenewswire·2025-12-02 22:29Core Insights - Class actions have been initiated on behalf of stockholders of Cepton, Inc. and MoonLake Immunotherapeutics, with specific deadlines for investors to petition the court to serve as lead plaintiff [1] MoonLake Immunotherapeutics - The lawsuit alleges that MoonLake Immunotherapeutics misled investors regarding its drug candidate sonelokimab (SLK), claiming it was superior to competing monoclonal antibodies [6] - The complaint states that MoonLake and its executives promoted SLK's Nanobody structure as having unique clinical advantages while failing to disclose it targeted the same molecules as UCB's BIMZELX and had no proven superiority [6] - Following the announcement of Phase 3 results on September 28, 2025, which showed SLK did not match BIMZELX's efficacy, MoonLake's stock fell nearly 90%, resulting in significant investor losses [6] - On September 29, 2025, MoonLake filed a current report with the SEC indicating that intercurrent events in the higher-than-expected placebo arm prevented the study from achieving statistical significance [6] - The stock plummeted 89.9% on September 29, 2025, following this news [6] Cepton, Inc. - The lawsuit against Cepton alleges that defendants made materially false and misleading statements and failed to disclose tax fraud and bribery to cover it up [6] - The complaint claims that as a result of these actions, the legal risks facing the company were understated, leading to materially false and misleading statements about its business and operations [6] - Investors suffered damages when the true details of the situation became public [6]